Advertisement
U.S. markets closed

CANbridge Pharmaceuticals Inc. (1228.HK)

HKSE - HKSE Delayed Price. Currency in HKD
0.3050.000 (0.00%)
At close: 03:39PM HKT

CANbridge Pharmaceuticals Inc.

Unit 18, 6th Floor
Building 21 No. 388 Xinping Street Suzhou Industrial Park
Suzhou
China
86 10 8414 8018
https://www.canbridgepharma.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees118

Key Executives

NameTitlePayExercisedYear Born
Dr. James Qun Xue M.B.A., Ph.D.Founder, Chairman of the Board, CEO & Member of Strategic Advisory Board5.52MN/A1970
Mr. Glenn HassanChief Financial OfficerN/AN/A1979
Dr. Pauline Li M.B.A., M.D.Senior VP of Clinical Development & OperationsN/AN/AN/A
Ms. Qian MaDirector of Legal & Compliance, Board Secretary and Joint Company SecretaryN/AN/AN/A
Ms. Stella MaoSenior Director of Public AffairsN/AN/AN/A
Ms. Chris ChenVice President of Human ResourcesN/AN/AN/A
Dr. Gerald F. Cox M.D., Ph.D.Chief Development Strategist & Interim Chief Medical OfficerN/AN/A1959
Mr. Marcelo ChereskyChief Commercial OfficerN/AN/A1966
Dr. Wei ZhangSenior Director & Head of CMC ChinaN/AN/AN/A
Ms. Rebecca ZhangSenior Vice President of Regulatory AffairsN/AN/AN/A
Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in HKD.

Description

CANbridge Pharmaceuticals Inc., a biopharmaceutical company, engages in the research, development, and commercialization of therapies for rare diseases and oncology indications worldwide. The company offers Hunterase, an enzyme replacement therapy for the treatment of Hunter syndrome; NERLYNX (Neratinlib), a potent irreversible tyrosine kinase inhibitor for HER2-positive breast cancer; and Caphosol Mouth Rinse for temporary and persistent dryness of the mouth and throat. It also engages in the development of CAN008, a glycosylation fusion protein that blocks the interaction between the CD95 receptor and its cognate ligand CD95L through binding to CD95L; CAN108, an orally administered small molecule ASBT inhibitor; CAN106, a recombinant human monoclonal antibody that specifically binds to and neutralizes C5 in the complement system; CAN103, a recombinant human enzyme replacement therapy (ERT); CAN107, a fibroblast growth factor 23 (FGF23) blocking antibody; CAN104, a recombinant human ERT; CAN105, a bispecific antibody; CAN201, a gene therapy program that utilizes adeno-associated virus (AAV) sL65 capsid; and CAN202, a gene therapy program utilizing AAV sL65 capsid. CANbridge Pharmaceuticals Inc. was founded in 2012 and is headquartered in Suzhou, China.

Corporate Governance

CANbridge Pharmaceuticals Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.